Publication Date:
2023-12-21
Description:
The analysis of circulating tumor cells (CTCs) as a real-time liquid biopsy approach can be used to obtain new insights into metastasis biology, and as companion diagnostics to improve the stratification of therapies and to obtain insights into the therapy-induced selection of cancer cells. In this book, we will cover all the different facets of CTCs to assemble a huge corpus of knowledge on cancer dissemination: technologies for their enrichment, detection, and characterization; their analysis at the single-cell level; their journey as CTC microemboli; their clinical relevance; their biology with the epithelial-to-mesenchymal transition (EMT); their stem-cell properties; their potential to initiate metastasis at distant sites; their ex vivo expansion; and their escape from the immune system.
Keywords:
R5-920
;
n/a
;
FOLFIRINOX
;
immunofluorescence imaging
;
AR-V7
;
circulating tumour cells
;
chemoradioresistance
;
CTC-based treatment decisions
;
rVAR2
;
immunophenotyping
;
immune system
;
CellSearch®
;
flow cytometry
;
clinical trials
;
circulating tumor DNA
;
synaptophysin
;
stem cells
;
colorectal cancer
;
melanoma
;
CTC biology
;
platelets
;
AR
;
CTC capture technology
;
castration resistant prostate cancer (CRPC)
;
PD-L1 expression
;
rovalpituzumab tesirine
;
HMB-45
;
thymidylate synthase
;
ctDNA
;
tumor cell dissemination
;
solid cancers
;
metastasis
;
locally advanced rectal cancer
;
miRNA
;
epithelial-to-mesenchymal transition (EMT)
;
NSCLC
;
tumor biomarkers
;
tumor stem cells
;
circulating tumor cells
;
major histocompatibility complex class I (MHCI)
;
bone marrow
;
heterogeneity
;
cerebrospinal liquid biopsy
;
fish
;
glioma
;
in vivo flow cytometry
;
colorectal surgery
;
CellSearch
;
single-cell analysis
;
disseminated tumor cells
;
EasyCount slides
;
microsatellite instability
;
circulating plasma cells
;
circulating leukemia cells
;
ARV7
;
SLUG
;
androgen receptor
;
metastatic colorectal cancer
;
leukocyte-derived extracellular vesicles
;
prostate cancer (PCa)
;
neutrophils
;
liquid biopsy
;
enzalutamide
;
CD133
;
enrichment and detection technologies
;
biomarkers
;
immune checkpoint inhibitors
;
biomarker
;
RAD23B
;
microbiome
;
integrin B1
;
ACCEPT
;
emboli
;
small-cell lung carcinoma
;
EPISPOT
;
microfluidics
;
early breast cancer
;
circulating tumor cells (CTC)
;
tumor-initiating cells (TICs)
;
immunomodulation
;
xenograft models
;
CTC-derived xenografts
;
malaria
;
circulating tumor cells (CTCs)
;
clinical utility
;
exosomes
;
liquid surgery
;
ctRNA
;
CTCs
;
epithelial–mesenchymal transition
;
targeted therapy
;
hematological cells
;
gene expression analysis
;
hepatocellular carcinoma (HCC)
;
breast cancer
;
EpCAM enrichment
;
prostate cancer
;
CTC
;
abiraterone
;
fibronectin
;
CTC-derived ex vivo models
;
CTMat
;
chromogranin A
;
CTM
;
exosome
;
bic Book Industry Communication::M Medicine
Language:
English
Format:
application/octet-stream
Permalink
